13,667 patients with a median follow-up of 36.4 months post-RP were stratified into BMI strata, with obese status assigned to those with a BMI > 29. In multivariate analysis, obese patients were significantly less likely to experience subsequent metastases post-RP (HR: 0.7, 95% CI: 0.5-0.98, p=0.03). In propensity score matched analysis, obesity was also associated with a decreased risk of metastases. However, while obesity correlated with immediate risk of metastases following “curative” treatment, Dr. Tennstedt and colleagues did not find a statistically significant difference in prostate cancer specific survival in either the Kaplan-Meier or propensity score matched analysis.
While obesity was associated with increases in overall mortality and prostate cancer metastases, a causative relationship has not been established. Overall, the improved management of BMI, diabetes mellitus, and metabolic syndrome remain key points for potential healthcare reform.
Presented By: Pierre Tennstedt, Martini-Klinik at University Medical Center
Authors: Pierre Tennstedt, Georg Salomon, Derya Tilki, Lars Budäus, Raisa Pompe, Sami-Ramzi Leyh-Bannurah, Alexander Haese, Hans Heinzer, Hartwig Huland, Markus Graefen, Jonas Schiffmann
Written By: Linda Huynh (BS), an assistant research specialist from the University of California, Irvine, on behalf of UroToday.com
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA